Cullinan Therapeutics, Inc. (CGEM)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
14.10 USD
-0.85
(-5.686%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 8:28 a.m. EDT
The investment thesis here is a classic biotech gamble: high-risk, high-reward based entirely on upcoming clinical trial results rather than current profitability. Fundamentally, the company is burning cash with negative free cash flow and no earnings, which keeps the long-term rating neutral despite the hype. However, the short-term outlook is building momentum. The options market is screaming bullishness, with traders stacking call exposure far above the money and establishing a protective floor via put writing. This asymmetry suggests the market is pricing in a binary event—likely the Phase 1 data mentioned in recent headlines—that could trigger a rapid re-rating. While the statistical forecast models are currently silent due to low confidence, the options flow indicates smart money is positioning for a breakout. The risk remains substantial given the lack of revenue, but the setup favors a tactical entry for those willing to ride the wave of potential clinical success. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.159184 |
| AutoTheta | 0.162108 |
| AutoETS | 0.163911 |
| AutoARIMA | 0.163912 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 5.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.080 |
| Excess Kurtosis | -0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.644 |
| Market Cap | 907,401,216 |
| Forward P/E | -5.60 |
| Beta | -0.04 |
| Previous Name | Cullinan Management, Inc. |
| Website | https://cullinantherapeutics.com |
As of Oct. 10, 2026, 8:28 a.m. EDT: Speculators are aggressively positioning for a significant upside move, evidenced by massive open interest and volume in out-of-the-money calls extending into late 2027 (strikes $25-$35). Conversely, put writing is heavy at lower strikes ($12-$17), creating a defined floor, while speculative put buying is concentrated further out at strikes $22-$30. This structure suggests a 'long gamma' bias where traders expect volatility expansion and a rally, betting on the company's clinical data catalysts to drive a gap-up scenario.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.9315245 |
| Address1 | One Main Street |
| Address2 | Suite 1350 |
| All Time High | 59.85 |
| All Time Low | 5.68 |
| Ask | 18.12 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 1,037,000 |
| Average Daily Volume3 Month | 875,651 |
| Average Volume | 875,651 |
| Average Volume10Days | 1,037,000 |
| Beta | -0.041 |
| Bid | 10.77 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.0 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 14.1 |
| Current Ratio | 8.417 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 14.93 |
| Day Low | 14.075 |
| Debt To Equity | 0.644 |
| Display Name | Cullinan Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,794,686,400 |
| Earnings Timestamp End | 1,794,686,400 |
| Earnings Timestamp Start | 1,794,686,400 |
| Ebitda | -221,488,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.596 |
| Enterprise Value | 574,934,208 |
| Eps Current Year | -3.12613 |
| Eps Forward | -2.51604 |
| Eps Trailing Twelve Months | -3.11 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 19.2424 |
| Fifty Day Average Change | -5.142399 |
| Fifty Day Average Change Percent | -0.26724312 |
| Fifty Two Week Change Percent | 93.15245 |
| Fifty Two Week High | 23.19 |
| Fifty Two Week High Change | -9.09 |
| Fifty Two Week High Change Percent | -0.3919793 |
| Fifty Two Week Low | 6.732 |
| Fifty Two Week Low Change | 7.3680005 |
| Fifty Two Week Low Change Percent | 1.0944742 |
| Fifty Two Week Range | 6.732 - 23.19 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,610,116,200,000 |
| Float Shares | 48,086,471 |
| Forward Eps | -2.51604 |
| Forward P E | -5.6040444 |
| Free Cashflow | -89,228,128 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 109 |
| Fullday Change | 0.049999237 |
| Fullday Change Percent | 0.3546045 |
| Fullday Price | 14.15 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00425 |
| Held Percent Institutions | 1.1264701 |
| Implied Shares Outstanding | 64,354,694 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-01-08 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Cullinan Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 907,401,216 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_539392639 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-14 |
| Net Income To Common | -208,343,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,085,020,140 |
| Number Of Analyst Opinions | 11 |
| Open | 14.86 |
| Operating Cashflow | -159,250,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 410 4650 |
| Pre Market Change | 0.049999237 |
| Pre Market Change Percent | 0.3546045 |
| Pre Market Price | 14.15 |
| Pre Market Time | 1,791,966,514 |
| Prev Name | Cullinan Management, Inc. |
| Previous Close | 14.95 |
| Price Eps Current Year | -4.510369 |
| Price Hint | 2 |
| Price To Book | 2.8200002 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.293 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.08333 |
| Region | US |
| Regular Market Change | -0.849999 |
| Regular Market Change Percent | -5.68561 |
| Regular Market Day High | 14.93 |
| Regular Market Day Low | 14.075 |
| Regular Market Day Range | 14.075 - 14.93 |
| Regular Market Open | 14.86 |
| Regular Market Previous Close | 14.95 |
| Regular Market Price | 14.1 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 590,349 |
| Return On Assets | -0.3136 |
| Return On Equity | -0.50298 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 64,354,694 |
| Shares Percent Shares Out | 0.118599996 |
| Shares Short | 7,634,127 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 10,371,763 |
| Short Name | Cullinan Therapeutics, Inc. |
| Short Percent Of Float | 0.16520001 |
| Short Ratio | 6.32 |
| Source Interval | 15 |
| State | MA |
| Symbol | CGEM |
| Target High Price | 42.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 33.45455 |
| Target Median Price | 35.0 |
| Total Cash | 334,537,984 |
| Total Cash Per Share | 5.198 |
| Total Debt | 2,071,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.11 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 15.524475 |
| Two Hundred Day Average Change | -1.4244747 |
| Two Hundred Day Average Change Percent | -0.09175671 |
| Type Disp | Equity |
| Volume | 590,349 |
| Website | https://cullinantherapeutics.com |
| Zip | 2,142 |